Breast Cancer Trial, Recruiting NCT07326800 Sponsor: Institut de Cancérologie de Lorraine Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Recruiting

NCT07326800
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with breast cancer that has not spread to other parts of the body (non-metastatic)
  • People who are willing and able to follow all the steps and procedures required by the study
  • People who have read, understood, and signed the consent form before joining
  • People who are covered by the social security system
  • People who are able to sit for 1.5-hour sessions during the study

Who may not be able to join:

  • People whose cancer has spread to other parts of the body (metastatic cancer)
  • People currently experiencing an acute (active and severe) psychiatric condition, such as severe depression, unstable bipolar disorder, or a psychotic disorder involving delusions or hallucinations
  • People who experience frequent, uncontrolled panic attacks, particularly those linked to strong health-related fears or anxiety
  • People who have significant difficulties with attention, memory, or thinking that may make participating in meditation difficult
  • People who have cognitive or neurological conditions that affect memory or thinking ability
  • People who are deaf
  • People who are currently taking part in another mindfulness program
  • People who are under legal guardianship, curatorship, or are otherwise deprived of their liberty
  • People for whom regular medical check-ins as part of the trial would not be possible due to geographic location, social circumstances, or psychological reasons

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: François Bourgognon, MD, Institut de Cancérologie de Lorraine

Phone: +33 3 83 59 84 00

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Institut de Cancérologie de Lorraine
Registry
ClinicalTrials.gov
Start date
16 February 2026
Est. completion
16 February 2029

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Demonstrate the efficacy of the MAEva program versus discussion group on quality of life in patients with non-metastatic breast cancer.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov